Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting

Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders

Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders

Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders